GlaxoSmithKline is trying to expand the market for its Benlysta drug beyond lupus by launching a major study of the medicine as a treatment for a serious blood vessel disorder.
GSK acquired full control of Benlysta when it bought Human Genome Sciences for $3 billion last year. Current sales of the drug are modest, at 70 million pounds ($106 million) in 2012, but GSK hopes it will become a major seller.
{iframe}http://www.reuters.com/article/2013/04/03/glaxosmithkline-benlysta-idUSL5N0CQ2NN20130403{/iframe}